QTERN (saxagliptin/dapagliflozin)

QTERN™ is a fixed dose combination of saxagliptin and dapagliflozin and is indicated in adults aged 18 years and older with type 2 diabetes mellitus1

Summary

QTERN™ improves glycaemic control whilst maintaining the additional benefits of FORXIGA® 1-5

Qtern positioning
Qtern positioning

 

When a metformin plus FORXIGA® patients' disease progresses, replace their FORXIGA® tablet with QTERN™.

FORXIGA® and QTERN™ are not indicated for the management of weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials.1,6

FORXIGA® and QTERN™ should not be initiated in patients with an eGFR <60 ml/min/1.73m2.1,6

FORXIGA® 10 mg is associated with low risk of hypoglycaemia when added to metformin. Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with FORXIGA®.6

If QTERN™ is used in combination with insulin secretagogue (sulphonylurea), a reduction in the dose of sulphonylurea may be required to minimise the risk of hypoglycaemia.1

Caution should be exercised in patients for whom a FORXIGA®-induced drop in blood pressure could pose a risk, and also in patients with aprior history of UTIs and GIs.6